Lophos Holdings Past Earnings Performance
Past criteria checks 0/6
Lophos Holdings's earnings have been declining at an average annual rate of -20.9%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually.
Key information
-20.9%
Earnings growth rate
4.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | -80.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Lophos Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -1 | 1 | 0 |
| 31 Dec 23 | 0 | -1 | 1 | 0 |
| 30 Sep 23 | 0 | -1 | 1 | 0 |
| 30 Jun 23 | 0 | -1 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
Quality Earnings: MESC is currently unprofitable.
Growing Profit Margin: MESC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MESC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MESC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MESC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-47.5%).
Return on Equity
High ROE: MESC has a negative Return on Equity (-80.73%), as it is currently unprofitable.